ES2093935T3 - Esquizofrenia. - Google Patents

Esquizofrenia.

Info

Publication number
ES2093935T3
ES2093935T3 ES93309286T ES93309286T ES2093935T3 ES 2093935 T3 ES2093935 T3 ES 2093935T3 ES 93309286 T ES93309286 T ES 93309286T ES 93309286 T ES93309286 T ES 93309286T ES 2093935 T3 ES2093935 T3 ES 2093935T3
Authority
ES
Spain
Prior art keywords
schizophrenia
efas
treated
combination
cell membrane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93309286T
Other languages
English (en)
Inventor
David Frederick Horrobin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scotia Holdings PLC
Original Assignee
Scotia Holdings PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Holdings PLC filed Critical Scotia Holdings PLC
Application granted granted Critical
Publication of ES2093935T3 publication Critical patent/ES2093935T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

LOS SINTOMAS NEGATIVOS DE ESQUIZOFRENIA Y/O BAJOS NIVELES DE MEMBRANA CELULAR DE EFAS PUEDEN SER TRATADOS CON UNA COMBINACION DE ACIDO ARAQUIDONICO Y ACIDO DOCOSAHEXANOICO.
ES93309286T 1992-11-26 1993-11-22 Esquizofrenia. Expired - Lifetime ES2093935T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929224809A GB9224809D0 (en) 1992-11-26 1992-11-26 Schizophrenia

Publications (1)

Publication Number Publication Date
ES2093935T3 true ES2093935T3 (es) 1997-01-01

Family

ID=10725730

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93309286T Expired - Lifetime ES2093935T3 (es) 1992-11-26 1993-11-22 Esquizofrenia.

Country Status (19)

Country Link
US (1) US5516800A (es)
EP (2) EP0733360A3 (es)
JP (1) JPH06199663A (es)
CN (1) CN1104494A (es)
AT (1) ATE144706T1 (es)
AU (2) AU666782B2 (es)
CA (1) CA2109777A1 (es)
DE (1) DE69305723T2 (es)
DK (1) DK0599576T3 (es)
ES (1) ES2093935T3 (es)
GB (1) GB9224809D0 (es)
GR (1) GR3021692T3 (es)
HK (1) HK114297A (es)
MY (1) MY109905A (es)
NO (1) NO934266L (es)
NZ (1) NZ250265A (es)
RU (1) RU2123844C1 (es)
SG (1) SG47838A1 (es)
ZA (1) ZA938835B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994392A (en) * 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US20050027004A1 (en) * 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
DK0707487T3 (da) * 1993-06-09 2004-08-02 Martek Biosciences Corp Fremgangsmåder og farmaceutiske præparater, der er nyttige til behandling af neurologiske lidelser
GB9510636D0 (en) * 1995-05-25 1995-07-19 Scotia Holdings Plc Fatty acid treatment
EP0831805A1 (en) * 1995-06-07 1998-04-01 Martek Biosciences Corporation Methods for controlling highly unsaturated fatty acid content in various tissues
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
DK0914116T3 (da) * 1996-05-22 2000-11-20 Protarga Inc Kompositstoffer omfattende konjugater af cis-docosahexaensyre og Taxotere
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
ATE236627T1 (de) 1996-10-11 2003-04-15 Scarista Ltd Pharmazeutische zubereitung enhaltend eicosapentaensäure und/oder stearidonsäure
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US6225444B1 (en) 1998-02-10 2001-05-01 Protarga, Inc. Neuroprotective peptides and uses thereof
DE69935995T3 (de) * 1998-10-15 2011-02-10 Dsm Ip Assets B.V. Polyungesättigen fettsäuren nährungsergänzung
GB9826899D0 (en) * 1998-12-08 1999-01-27 Knoll Ag Methods to treat depression and other psychiatric disorders and assays for compounds
EA200100662A1 (ru) * 1998-12-15 2001-12-24 Американ Хоум Продактс Корпорейшн Способ и композиция для поддержания и восстановления целостности кишки
GB9901808D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Drugs for treatment of psychiatric and brain disorders
US7235583B1 (en) 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
GB9923738D0 (en) * 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
GB0016045D0 (en) * 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
AU2002303164A1 (en) 2001-03-23 2002-10-08 Protarga, Inc. Fatty amine drug conjugates
JP4634694B2 (ja) * 2001-03-23 2011-02-16 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド 脂肪アルコール薬物複合体
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
WO2005072306A2 (en) * 2004-01-19 2005-08-11 Martek Biosciences Corporation Reelin deficiency or dysfunction and methods related thereto
ITMI20040069A1 (it) * 2004-01-21 2004-04-21 Tiberio Bruzzese Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
ITMI20051560A1 (it) * 2005-08-10 2007-02-11 Tiberio Bruzzese Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
EP1772146A1 (en) * 2005-10-03 2007-04-11 Neuropharma, S.A. Polyunsaturated fatty acids as bace inhibitors
US8637321B2 (en) * 2005-10-24 2014-01-28 Duke University Lipidomics approaches for central nervous system disorders
US8137977B2 (en) * 2006-04-24 2012-03-20 Children's Hospital & Research Center At Oakland Lipidomic approaches to determining drug response phenotypes in cardiovascular disease
WO2008081989A1 (ja) 2006-12-28 2008-07-10 Suntory Holdings Limited 神経再生剤
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
EP2211881A4 (en) * 2007-11-01 2012-01-04 Wake Forest University School Of Medicine COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING DISEASES AFFECTING MAMMALS
GB2460056A (en) * 2008-05-14 2009-11-18 Arab Science & Technology Foun Compositions comprising omega-6 fatty acids for use in treating schistosomiasis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882352A (en) * 1986-07-28 1989-11-21 Nelson Research & Development Co. Method for treating schizophrenia
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
US4588721A (en) * 1983-09-12 1986-05-13 The Upjohn Company Treatment of negative symptoms of schizophrenia
US4526902A (en) * 1983-10-24 1985-07-02 Century Laboratories, Inc. Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
GB8603621D0 (en) * 1986-02-14 1986-03-19 Habib N Modifying lipid structure of cell membranes
GB8714772D0 (en) * 1987-06-24 1987-07-29 Efamol Ltd Essential fatty acid compositions
US5198468A (en) * 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
GB8715914D0 (en) * 1987-07-07 1987-08-12 Efamol Ltd Treatment of cerabral disorders
FR2619712B1 (fr) * 1987-08-25 1990-08-31 Rhone Poulenc Sante Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la schizophrenie
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
HU208484B (en) * 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
DE3920679A1 (de) * 1989-06-23 1991-01-10 Milupa Ag Fettmischung zur herstellung von nahrungen, insbesondere saeuglingsnahrungen
DE4017979A1 (de) * 1990-06-05 1991-12-12 Meyer Lucas Gmbh & Co Lipid- bzw. phospholipid-zusammensetzungen sowie diese enthaltendes mittel zur behandlung von erkrankungen sowie auf die zellmembrane zurueckzufuehrende stoerungen
US5070101A (en) * 1991-02-14 1991-12-03 Mount Sinai School Of Medicine Of The City University Of New York Method and pharmaceutical composition for the treatment of schizophrenia

Also Published As

Publication number Publication date
NO934266D0 (no) 1993-11-25
EP0599576B1 (en) 1996-10-30
ZA938835B (en) 1994-08-02
CN1104494A (zh) 1995-07-05
DK0599576T3 (da) 1996-11-25
DE69305723T2 (de) 1997-04-03
CA2109777A1 (en) 1994-05-27
AU5183093A (en) 1994-06-09
EP0599576A1 (en) 1994-06-01
SG47838A1 (en) 1998-04-17
DE69305723D1 (de) 1996-12-05
NO934266L (no) 1994-05-27
EP0733360A3 (en) 1996-10-02
RU2123844C1 (ru) 1998-12-27
MY109905A (en) 1997-09-30
GR3021692T3 (en) 1997-02-28
JPH06199663A (ja) 1994-07-19
US5516800A (en) 1996-05-14
AU5232996A (en) 1996-07-18
GB9224809D0 (en) 1993-01-13
NZ250265A (en) 1997-06-24
AU666782B2 (en) 1996-02-22
ATE144706T1 (de) 1996-11-15
HK114297A (en) 1997-08-29
EP0733360A2 (en) 1996-09-25

Similar Documents

Publication Publication Date Title
DE69305723D1 (de) Schizophrenie
RU93052390A (ru) Способ лечения шизофрении, применение комбинации арахидоновой и докозагексановой кислот для получения лекарственного средства для лечения шизофрении
ES2055197T3 (es) Una composicion que contiene d-cicloserina y d-alanina para el aumento de la memoria y el aprendizaje o el tratamiento de un trastorno cognitivo o psicotico.
FI944424A (fi) Elektrolyysikenno sterilointiliuosten valmistamiseksi joilla on suurempi otsonipitoisuus
NO931923D0 (no) Fettsyre-behandling
ATE121086T1 (de) Sulfonylbenzyl-substituierte benzo- und pyridopyridone.
DE69422763D1 (de) Verteilte negative Torstromversorgung
FI832592A (fi) Foerfarande foer att utfoera elektromikrobiella reduktioner
NL940019I2 (nl) Remming van het infecterende karakter in vitro en het cytopatische effect van HTV-III/LAV door 2',3-didesoxycytidine.
FI915929A (fi) Anti-herpes kastanosperminestrar.
ATE41940T1 (de) Wasserloesliche copolymerisate und deren verwendung als baustoffhilfsmittel.
ITMI910380A1 (it) Composti steroidei attivi sul sistema cardiovascolare
ATE51520T1 (de) Kosmetikum.
DK435089D0 (da) Anvendelse af zofenopril til behandling af rheumatoid arthritis
ATE45724T1 (de) Okuloselektive betablocker.
KR880016581U (ko) 정수 및 살균장치가 장착된 가습기
DE69327750D1 (de) Negativ rückgekoppelter Abfühlvorverstärker
ES2173158T3 (es) Reduccion del tejido adiposo utilizando colagenasa
KR940020702U (ko) 산소의 용존량을 증가시키기 위한 폭기장치
UA8391A1 (uk) Джерело живлення
DK356689D0 (da) Optisk forstaerker med nedsat ulinearitet
FI931521A0 (fi) Negativ vridvinkel
SE8500548L (sv) Skyddsrum

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 599576

Country of ref document: ES